A phase 3 study evaluating efficacy and safety of Bovine-rotavirus-vaccine-reassortant
Phase of Trial: Phase III
Latest Information Update: 05 Oct 2018
Price : $35 *
At a glance
- Drugs Bovine rotavirus vaccine reassortant (Primary)
- Indications Rotavirus infections
- Focus Pharmacodynamics
- 05 Oct 2018 New trial record
- 27 Sep 2018 According to a PATH media release, ROTASIIL achieved World Health Organization's (WHO's) prequalification Based on data from this and another study CTP700262299.
- 27 Sep 2018 According to a PATH media release, Medecins Sans Frontieres and Epicentre have conducted this study.